Sotagliflozin


Sotagliflozin is a drug approved in EU for certain patients with type I diabetes.
The Food and Drug Administration refused its approval for use in combination with insulin for the treatment of type 1 diabetes. It is developed by Sanofi.
Sotagliflozin is a sodium/glucose cotransporter 2 inhibitor and is in the class of drugs known as gliflozins.